Version history

{
  "session_id": "sess-gap-pubmed-20260410-150544-e3a2eab9-task-c747c608",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\"ranked_hypotheses\":[{\"title\":\"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis\",\"description\":\"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2 on microglia, shifting neuroinflammatory profile from pro-inflammatory (IL-1β, TNF-α, IL-6) to anti-inflammatory/regulatory (IL-10, TGF-β). This represents the most druggable pharmacology story, though the field's first major TREM2 agonist phase 2 (AL002) missed its clinical primary endpoint despite biomarker engagement. Clinical translation requires biomarker-enriched populations and likely combination therapy with anti-amyloid antibodies.\",\"target_gene\":\"TREM2/TYROBP\",\"dimension_scores\":{\"evidence_strength\":0.72,\"novelty\":0.55,\"feasibility\":0.80,\"therapeutic_potential\":0.65,\"mechanistic_plausibility\":0.70,\"druggability\":0.75,\"safety_profile\":0.50,\"competitive_landscape\":0.40,\"data_availability\":0.70,\"reproducibility\":0.65},\"composite_score\":0.64,\"evidence_for\":[{\"claim\":\"TREM2 stimulation suppresses LPS-induced inflammatory cytokines in primary microglia\",\"pmid\":\"31217397\"},{\"claim\":\"CST3 transgenic overexpression reduces neuroinflammation in 3xTg AD mice\",\"pmid\":\"29227873\"},{\"claim\":\"Cancer patients show elevated systemic cystatin C and reduced CSF inflammatory markers\",\"pmid\":\"41576952\"}],\"evidence_against\":[{\"claim\":\"AL002 phase 2 TREM2 agonist showed CNS target engagement but missed clinical primary endpoint in early AD\",\"pmid\":\"31235932\"},{\"claim\":\"Broad anti-inflammatory effects could paradoxically impair beneficial debris clearance\",\"pmid\":\"31776517\"}]},{\"title\":\"Peri-plaque tau seeding restraint via TREM2-competent microglia\",\"description\":\"TREM2-activated microglia limit neuritic plaque tau spread around amyloid plaques through enhanced phagocytosis of extracellular tau seeds, consistent with Leyns et al. This is the best tau-facing survivor but applies only in mixed amyloid-tau biology, not pure tauopathy. The Li et al. 2026 Cell paper showed no effect on tau in rTg4510 mice (pure tauopathy), which is consistent with this hypothesis.\",\"target_gene\":\"TREM2\",\"dimension_scores\":{\"evidence_strength\":0.60,\"novelty\":0.65,\"feasibility\":0.65,\"therapeutic_potential\":0.60,\"mechanistic_plausibility\":0.62,\"druggability\":0.55,\"safety_profile\":0.55,\"competitive_landscape\":0.50,\"data_availability\":0.60,\"reproducibility\":0.58},\"composite_score\":0.59,\"evidence_for\":[{\"claim\":\"TREM2 loss-of-function variants accelerate tau pathology in human AD\",\"pmid\":\"29689295\"},{\"claim\":\"TREM2-activated microglia show increased phagocytosis of apoptotic neurons\",\"pmid\":\"31217397\"},{\"claim\":\"Negative rTg4510 tau result consistent with amyloid-context limitation\",\"pmid\":\"41576952\"}],\"evidence_against\":[{\"claim\":\"TREM2 deficiency can also reduce tau seeding propagation in specific contexts\",\"pmid\":\"31776517\"},{\"claim\":\"Chronically activated microglia show impaired phagocytosis\",\"pmid\":\"30759353\"}]},{\"title\":\"Synaptic protection via microglial/complement normalization\",\"description\":\"Cancer-induced cystatin C prevents complement-mediated synaptic loss through TREM2-mediated microglial phenotype regulation, reducing C1q/C3 deposition and excessive pruning. This is clinically important but probably secondary to plaque remodeling plus microglial state change rather than a distinct mechanism. Synaptic biomarkers are noisy and slower-moving than amyloid PD markers, making mechanism proof difficult in humans.\",\"target_gene\":\"TREM2/complement cascade\",\"dimension_scores\":{\"evidence_strength\":0.55,\"novelty\":0.50,\"feasibility\":0.60,\"therapeutic_potential\":0.65,\"mechanistic_plausibility\":0.58,\"druggability\":0.50,\"safety_profile\":0.55,\"competitive_landscape\":0.60,\"data_availability\":0.55,\"reproducibility\":0.52},\"composite_score\":0.56,\"evidence_for\":[{\"claim\":\"TREM2 deficiency causes abnormal synaptic pruning and memory deficits\",\"pmid\":\"29991702\"},{\"claim\":\"Cystatin C prevents excitotoxic synapse loss in vitro\",\"pmid\":\"20127989\"},{\"claim\":\"Complement inhibition reduces synaptic loss in AD mouse models\",\"pmid\":\"30867593\"}],\"evidence_against\":[{\"claim\":\"TREM2 loss-of-function shows baseline requirement, not that activation improves pruning\",\"pmid\":\"29991702\"},{\"claim\":\"Cachexia confounding in cancer-bearing mice may affect synaptic plasticity independently\",\"pmid\":\"NA\"}]},{\"title\":\"TREM2-dependent microglial phagocytosis of tau seeds\",\"description\":\"Cystatin-C-activated TREM2 microglia reduce tau pathology through enhanced phagocytosis of extracellular tau seeds. Critical limitation: microglial phagocytosis can only address extracellular seeds, not intracellular neurofibrillary tangles. This severely limits therapeutic scope to disease prevention rather than modification of established pathology.\",\"target_gene\":\"TREM2/Syk/PLCγ2\",\"dimension_scores\":{\"evidence_strength\":0.50,\"novelty\":0.60,\"feasibility\":0.55,\"therapeutic_potential\":0.55,\"mechanistic_plausibility\":0.52,\"druggability\":0.50,\"safety_profile\":0.55,\"competitive_landscape\":0.55,\"data_availability\":0.50,\"reproducibility\":0.48},\"composite_score\":0.53,\"evidence_for\":[{\"claim\":\"TREM2 loss-of-function accelerates tau pathology in human AD\",\"pmid\":\"29689295\"},{\"claim\":\"Cystatin C colocalizes with amyloid plaques\",\"pmid\":\"26653636\"}],\"evidence_against\":[{\"claim\":\"TREM2 gain-of-function not demonstrated to reduce tau pathology\",\"pmid\":\"31776517\"},{\"claim\":\"Extracellular tau seeds are only one pool; intracellular NFTs remain unaffected\",\"pmid\":\"NA\"}]},{\"title\":\"Tumor-derived extracellular vesicles as TREM2 ligands\",\"description\":\"Tumor extracellular vesicles carrying phosphatidylserine activate microglia via TREM2, enhancing neuroprotective functions. This is interesting discovery biology but not trial-ready. Requires characterization of PS exposure, EV cargo composition, and demonstration that EVs directly mediate the cystatin-C effect.\",\"target_gene\":\"TREM2 ligands on tumor EVs\",\"dimension_scores\":{\"evidence_strength\":0.45,\"novelty\":0.70,\"feasibility\":0.45,\"therapeutic_potential\":0.50,\"mechanistic_plausibility\":0.50,\"druggability\":0.40,\"safety_profile\":0.55,\"competitive_landscape\":0.70,\"data_availability\":0.40,\"reproducibility\":0.42},\"composite_score\":0.49,\"evidence_for\":[{\"claim\":\"TREM2 binds phosphatidylserine on apoptotic cells\",\"pmid\":\"31118453\"},{\"claim\":\"Tumor EVs transfer functional cargo to recipient cells\",\"pmid\":\"NA\"}],\"evidence_against\":[{\"claim\":\"Mechanism requires demonstration that EVs are necessary for cystatin-C effect\",\"pmid\":\"41576952\"}]},{\"title\":\"Synergistic reduction of amyloid-tau interaction through secondary effects\",\"description\":\"Cancer/cystatin-C-mediated amyloid reduction decreases amyloid-nucleated tau pathology through reduced BACE1 activity and GSK3β activation. This hypothesis is almost certainly true but uninformative—it re-explains known downstream biology rather than identifying a novel mechanism. Should be demoted from 'mechanism' to 'expected downstream consequence of amyloid lowering.'\",\"target_gene\":\"BACE1/GSK3β\",\"dimension_scores\":{\"evidence_strength\":0.65,\"novelty\":0.25,\"feasibility\":0.70,\"therapeutic_potential\":0.40,\"mechanistic_plausibility\":0.60,\"druggability\":0.35,\"safety_profile\":0.50,\"competitive_landscape\":0.30,\"data_availability\":0.65,\"reproducibility\":0.60},\"composite_score\":0.50,\"evidence_for\":[{\"claim\":\"Chronic peripheral inflammation elevates BACE1 and increases Aβ production\",\"pmid\":\"29227873\"},{\"claim\":\"Amyloid plaque reduction via BACE inhibitors reduces tau PET signal in humans\",\"pmid\":\"NA\"}],\"evidence_against\":[{\"claim\":\"BACE1 inhibitors failed clinically despite amyloid reduction\",\"pmid\":\"NA\"},{\"claim\":\"Circular reasoning: reducing amyloid reduces tau is expected, not novel\",\"pmid\":\"NA\"}]},{\"title\":\"Direct cystatin C inhibition of tau aggregation\",\"description\":\"Cystatin C binds tau through its cystatin-like domain, sequestering monomeric tau and preventing β-sheet aggregation. This hypothesis has the weakest mechanistic foundation: cystatin C is secreted (extracellular) while tau is predominantly intracellular. The 2005 Co-IP has not been independently replicated in 20+ years. At physiologically relevant concentrations (10-50 nM CSF), any inhibitory effect may be negligible.\",\"target_gene\":\"CST3/MAPT interaction\",\"dimension_scores\":{\"evidence_strength\":0.30,\"novelty\":0.55,\"feasibility\":0.30,\"therapeutic_potential\":0.45,\"mechanistic_plausibility\":0.28,\"druggability\":0.25,\"safety_profile\":0.60,\"competitive_landscape\":0.65,\"data_availability\":0.35,\"reproducibility\":0.22},\"composite_score\":0.39,\"evidence_for\":[{\"claim\":\"Cystatin C co-immunoprecipitates with tau in human brain tissue (unreplicated)\",\"pmid\":\"16253072\"},{\"claim\":\"CST3 polymorphisms associate with differential AD risk in some meta-analyses\",\"pmid\":\"NA\"}],\"evidence_against\":[{\"claim\":\"Localization paradox: extracellular cystatin C vs intracellular tau\",\"pmid\":\"NA\"},{\"claim\":\"Co-IP not independently replicated in 20+ years\",\"pmid\":\"NA\"},{\"claim\":\"Species conservation mismatch suggests species-specific artifact\",\"pmid\":\"NA\"}]},{\"title\":\"TREM2-independent neuronal protection via cystatin-C/LRP2 signaling\",\"description\":\"Cystatin C directly protects neurons against excitotoxicity through LRP2 (megalin) receptor engagement and AKT/ERK survival signaling. Critical weaknesses: neuronal LRP2 expression is technically challenging to detect and primarily studied in developmental contexts; systemic cystatin C must cross both BBB and neuronal membrane to engage LRP2—a two-membrane traversal problem with low probability.\",\"target_gene\":\"CST3/LRP2/AKT/ERK\",\"dimension_scores\":{\"evidence_strength\":0.35,\"novelty\":0.50,\"feasibility\":0.30,\"therapeutic_potential\":0.40,\"mechanistic_plausibility\":0.32,\"druggability\":0.25,\"safety_profile\":0.60,\"competitive_landscape\":0.70,\"data_availability\":0.35,\"reproducibility\":0.30},\"composite_score\":0.41,\"evidence_for\":[{\"claim\":\"CST3-LRP2 interaction demonstrated in kidney proximal tubules\",\"pmid\":\"24212290\"},{\"claim\":\"Cystatin C is neuroprotective in ischemia models\",\"pmid\":\"18083121\"}],\"evidence_against\":[{\"claim\":\"Neuronal LRP2 protein detection is technically challenging\",\"pmid\":\"NA\"},{\"claim\":\"Two-membrane BBB traversal problem\",\"pmid\":\"NA\"},{\"claim\":\"High circulating cystatin C in renal disease associated with mortality, not neuroprotection\",\"pmid\":\"NA\"}]}],\"knowledge_edges\":[{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"TREM2\",\"target_type\":\"gene\",\"relation\":\"activates_microglial_phagocytosis\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"TREM2\",\"target_type\":\"gene\",\"relation\":\"activates_anti-inflammatory_reprogramming\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"TYROBP\",\"target_type\":\"gene\",\"relation\":\"signals_via_DAP12\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"TREM2\",\"target_type\":\"gene\",\"relation\":\"modulates_complement_cascade\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"C1QA\",\"target_type\":\"gene\",\"relation\":\"reduces_synaptic_deposition\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"C3\",\"target_type\":\"gene\",\"relation\":\"reduces_synaptic_deposition\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"CST3\",\"target_type\":\"gene\",\"relation\":\"binds_tau_to_prevent_aggregation\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"MAPT\",\"target_type\":\"gene\",\"relation\":\"binds_cystatin_C_to_prevent_fibrillization\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"CST3\",\"target_type\":\"gene\",\"relation\":\"engages_neuronal_LRP2\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"LRP2\",\"target_type\":\"gene\",\"relation\":\"activates_AKT_ERK_survival_pathway\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"BACE1\",\"target_type\":\"gene\",\"relation\":\"reduced_by_amyloid_normalization\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"GSK3B\",\"target_type\":\"gene\",\"relation\":\"reduced_by_ER_stress_normalization\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"TREM2\",\"target_type\":\"gene\",\"relation\":\"activated_by_tumor_EV_phosphatidylserine\"},{\"source_id\":\"source_paper\",\"source_type\":\"evidence\",\"target_id\":\"CST3\",\"target_type\":\"gene\",\"relation\":\"elevated_by_peripheral_cancer\"},{\"source_id\":\"source_paper\",\"source_type\":\"evidence\",\"target_id\":\"TREM2\",\"target_type\":\"gene\",\"relation\":\"engaged_by_elevated_cystatin_C\"},{\"source_id\":\"AL002_trial\",\"source_type\":\"evidence\",\"target_id\":\"TREM2\",\"target_type\":\"gene\",\"relation\":\"phase_2_missed_clinical_endpoint\"}],\"synthesis_summary\":\"The cancer-cystatin-C-TREM2 pathway is feasible as an amyloid-linked microglial modulation strategy, not as a broad disease-modifying solution addressing tau, neuroinflammation, and synaptic loss simultaneously. The February 2026 Li et al. Cell paper demonstrated amyloid reduction but showed no effect on tau in pure rTg4510 tauopathy mice, while the March 2026 AL002 phase 2 TREM2 agonist trial missed its clinical primary endpoint despite biomarker engagement—substantially raising the translational bar for any TREM2-based program. Three hypotheses survive as amyloid-context, microglia-mediated adjunct strategies: (1) peri-plaque tau seeding restraint via TREM2-competent microglia in mixed amyloid-tau biology; (2) synaptic protection via microglial/complement normalization as a secondary effect; and (3) anti-inflammatory microglial reprogramming as the most druggable but least differentiated pathway. Hypotheses 2 (direct cystatin-C-tau binding) and 5 (neuronal LRP2 protection) should be dropped due to weak mechanistic support and poor translational leverage. Hypothesis 6 should be demoted from 'novel mechanism' to 'expected downstream consequence of amyloid lowering.' Hypothesis 7 (tumor EVs as TREM2 ligands) represents interesting discovery biology but is not development-ready. The best development thesis is: use TREM2/cystatin-C biology to improve plaque-associated microglial function in early amyloid-positive AD, then test whether that secondarily reduces peri-plaque tau spread and synaptic injury—anything stronger than this is ahead of the evidence.\"}",
  "tokens_used": "3513",
  "persona_id": "persona-synthesizer"
}